Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer
Our exploratory findings indicate that CloneSight could be a promising tool for MRD detection and relapse prediction, providing a cost-effective, patient-informed approach to ctDNA monitoring. The ability of this approach to detect relapse prior to clinical recurrence suggests its potential relevance in improving patient monitoring. These findings suggest that ctDNA-based MRD assays could play a role in future surveillance strategies for HR + BC, though further studies in larger cohorts are needed to confirm their clinical applicability.
Authors
- Javier Pascual (ORCID: https://orcid.org/0000-0003-3874-2782)
- Jesús Velasco-Suelto
- Emilio Alba (ORCID: https://orcid.org/0000-0002-3364-2603)
- Ángel Guerrero‐Zotano (ORCID: https://orcid.org/0000-0003-0318-9120)
- Alejandro Martín-Muñoz (ORCID: https://orcid.org/0000-0002-5180-5760)
- María Elena Quirós-Ortega (ORCID: https://orcid.org/0000-0001-7725-6168)
- Yanira Heredia
- Esperanza López-López
- Iñaki Comino‐Méndez (ORCID: https://orcid.org/0000-0003-1926-9432)
- Celia Gaona-Romero
- Patricia Losana
Institutions
- Altarum Institute (US)
- Fundación Instituto Valenciano de Oncología (ES)
- Centro Nacional de Epidemiología (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- Universidad de Málaga (ES)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1186/s13058-025-02016-7
- Citations
- 7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 6.55
Funders
- Pfizer
- Centro de Investigación Biomédica en Red de Cáncer
- Agencia Estatal de Investigación